In vitro characterization of a small molecule inhibitor of the alanine serine cysteine transporter -1 (SLC7A10)

Journal of Neurochemistry

Volumn 129, Issue 2, 2014, Pages 275-283

  Brown, Jeffrey M ^a   Hunihan, Lisa ^a   Prack, Margaret M ^a   Harden, David G ^a   Bronson, Joanne ^a   Dzierba, Carolyn D ^a   Gentles, Robert G ^a   Hendricson, Adam ^a   Krause, Rudy ^a   Macor, John E ^a   Westphal, Ryan S ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b EnVivo Pharmaceuticals   (United States)

Author keywords

amino acid transporter; cognition; D serine; glutamate; NMDA; schizophrenia

Indexed keywords

ALANINE SERINE CYSTEINE TRANSPORTER 1; ALANINE SERINE CYSTEINE TRANSPORTER 1 INHIBITOR; AMINO ACID TRANSPORTER; BMS 466442; DEXTRO SERINE; GLYCINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SYNAPSE;

AMINO ACID TRANSPORTER; COGNITION; D-SERINE; GLUTAMATE; NMDA; SCHIZOPHRENIA;

AMINO ACID TRANSPORT SYSTEM Y+; AMINO ACIDS; ANIMALS; CELL LINE; CEREBRAL CORTEX; EXCITATORY AMINO ACID AGONISTS; GLYCINE; HISTIDINE; HUMANS; INDOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; SMALL MOLECULE LIBRARIES; SYNAPTOSOMES;

EID: 84897975702     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12618     Document Type: Article

References (33)

1. Adler C. M., Malhotra A. K., Elman I., Goldberg T., Egan M., Pickar D., and, Breier A., (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 10, 1646-1649.
2. Balu D. T., Li Y., Puhl M. D., Benneyworth M. A., Basu A. C., Takagi S., Bolshakov V. Y., and, Coyle J. T., (2013) Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl Acad. Sci. USA 110, E2400-E2409.
3. Black M. D., Varty G. B., Arad M., Barak S., De Levie A., Boulay D., Pichat P., Griebel G., and, Weiner I., (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202, 385-396.
4. Bröer A., Wagner C. A., Lang F., and, Bröer S., (2000) The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem. J. 355, 787-795.
5. Brown J.M., Li J.J., and, Sinz M.W,. (2010) Antipsychotic a gents in Burger's Medicinal Chemistry, Drug Discovery, and Development (, Donald J., Abraham D. J., David P., and, Rotella D. P.,. eds), Seventh Edition, pp. 161-218. John Wiley & Sons, Inc, Indianapolis, IN, USA.
6. Fukasawa Y., Segawa H., Kim J. Y., Chairoungdua A., Kim D. K., Matsuo H., Cha S. H., Endou H., and, Kanai Y., (2000) Identification and Characterization of a Na+-independent Neutral Amino Acid Transporter That Associates with the 4F2 Heavy Chain and Exhibits Substrate Selectivity for Small Neutral d- and l-Amino Acids. J. Biol. Chem. 13, 9690-9698.
7. Gliddon C. M., Shao Z., LeMaistre J. L., and, Anderson C. M., (2009) Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain. J. Neurochem. 108, 372-383.
8. Harada K., Nakato K., Yarimizu J., et al,. (2012) A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)- 4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur. J. Pharmacol. 685, 59-69.
9. Haughey H. M., Brown J. M., Wilkins D. G., Hanson G. R., and, Fleckenstein A. E., (2000) Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Res. 863, 59-65.
10. Helboe L., Egebjerg J., Møller M., and, Thomsen C., (2003) Distribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. Eur. J. Neurosci. 8, 2227-2238.
11. Heresco-Levy U., Javitt D. C., Ermilov M., Mordel C., Horowitz A., and, Kelly D., (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 169, 610-617.
12. Heresco-Levy U., Javitt D. C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., and, Ermilov M., (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577-585.
13. Javitt D. C., Zylberman I., Zukin S. R., Heresco-Levy U., and, Lindenmayer J. P., (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234-1236.
14. Jentsch J. D., Redmond D. E. Jr, Elsworth J. D., Taylor J. R., Youngren K. D., and, Roth R. H,. (1997a) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 27, 953-955
15. Jentsch J. D., Tran A., Le D., Youngren K. D., and, Roth R. H., (1997b) Subchronic Phencyclidine Administration Reduces Mesoprefrontal Dopamine Utilization and Impairs Prefrontal Cortical-Dependent Cognition in the Rat. Neuropsychopharmacology 17, 92-99.
16. Kantrowitz J. T., Malhotra A. K., Cornblatt B., Silipo G., Balla A., Suckow R. F., D'Souza C., Saksa J., Woods S. W., and, Javitt D. C., (2010) High dose D-serine in the treatment of schizophrenia. Schizophr. Res. 121, 125-130.
17. Malhotra A. K., Pinals D. A., Weingartner H., Sirocco K., Missar C. D., Pickar D., and, Breier A., (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14, 301-307.
18. Nakauchi J., Matsuo H., Kim D. K., et al,. (2000) Cloning and characterization of a human brain Na(+)-independent transporter for small neutral amino acids that transports D-serine with high affinity. Neurosci. Lett. 287, 231-235.
19. Nikiforuk A., Kos T., Rafa D., Behl B., Bespalov A., and, Popik P., (2011) Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 6, 262-267.
20. Oliet S. H., and, Mothet J. P., (2006) Molecular determinants of D-serine-mediated gliotransmission: from release to function. Glia 54, 726-737.
21. Orozco-Ibarra M., Medina-Campos O. N., Sánchez-González D. J., Martínez-Martínez C. M., Floriano-Sánchez E., Santamaría A., Ramirez V., Bobadilla N. A., and, Pedraza-Chaverri J., (2007) Evaluation of oxidative stress in D-serine induced nephrotoxicity. Toxicology 229, 123-125.
22. Pineda M., Fernández E., Torrents D., Estévez R., Lõpez C., Camps M., Lloberas J., Zorzano A., and, Palacín M., (1999) Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J. Biol. Chem. 274, 19738-19744.
23. Rosenberg D., Artoul S., Segal A. C., et al,. (2013) Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity. J. Neurosci. 33, 3533-3544.
24. Rutter A. R., Fradley R. L., Garrett E. M., Chapman K. L., Lawrence J. M., Rosahl T. W., and, Patel S., (2007) Evidence from gene knockout studies implicates asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur. J. Neurosci. 25, 1757-1766.
25. Schell M. J., Brady R. O., Jr, Molliver M. E., and, Snyder S. H., (1997) D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J. Neurosci. 17, 1604-1615.
26. Singh S. P., and, Singh V., (2011) Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25, 859-885.
27. Stefani M. R., and, Moghaddam B., (2005) Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol. Psychiatry 57, 433-436.
28. Tsai G., Yang P., Chung L. C., Lange N., and, Coyle J. T., (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081-1089.
29. Utsunomiya-Tate N., Endou H., and, Kanai Y., (1996) Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter. J. Biol. Chem. 271, 14883-14890.
30. Verrey F., Closs E. I., Wagner C. A., Palacin M., Endou H., and, Kanai Y., (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 477, 532-542.
31. Williams R. E., and, Lock E. A., (2004) D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism. Toxicology 20, 231-238.
32. Xie X., Dumas T., Tang L., et al,. (2005) Lack of the alanine-serine-cysteine transporter 1 causes tremors, seizures, and early postnatal death in mice. Brain Res. 1052, 212-221.
33. Yanagida O., Kanai Y., Chairoungdua A., et al,. (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta 1514, 291-292.